Phathom Must Now Hold $119.3 Million In Cash For Its Royalty Lenders As A Lawsuit Targets VOQUEZNA Exclusivity

The cash floor on Phathom's royalty financing rose from $30 million on October 1, while generic-drug filers challenge its exclusivity.

Share
Phathom Must Now Hold $119.3 Million In Cash For Its Royalty Lenders As A Lawsuit Targets VOQUEZNA Exclusivity

Phathom Pharmaceuticals, which sells the acid-blocking drug VOQUEZNA for gastrointestinal diseases, said in its quarterly report filed Thursday that the minimum cash required under its royalty financing agreement is $119.3 million as of October 1. The floor was a flat $30 million through September 30, and it arrives as a lawsuit and an FDA comment docket put the exclusivity behind its products in play.

A cash floor that steps up each October

The covenant is a percentage of the $275 million the investors funded, less the royalties they have already received. That percentage is 50% from October 1, 2026, 75% from October 1, 2027 and 100% from October 1, 2028, running through September 30, 2029. The company said it was in compliance at September 30.

Phathom held $184.6 million in cash at September 30, up from $130.0 million at year-end. Its separate Hercules loan, with $175 million outstanding, requires cash of 20% of principal at all times.

The revenue interest liability carried a value of $387.5 million at September 30, against $377.4 million at year-end, even after $19.0 million of royalty payments and payables. Investors have received $36.4 million in total. They are entitled to a 10% royalty on net sales of vonoprazan products, which ends once they have collected 200% of their investment.

The exclusivity fight

BDR Pharmaceuticals sued the FDA in federal court in Washington, challenging how the agency applied the GAIN Act to extend VOQUEZNA's new-chemical-entity exclusivity. Phathom announced the suit in an 8-K on October 23. The FDA granted the extension in June 2025 and recognizes exclusivity through May 3, 2032.

The agency has opened a public docket, with comments due November 23, and a second generic filer, Saba, said it plans to move to consolidate its case with BDR's, according to a second 8-K. Phathom said the court granted its motion to intervene on October 26.

The 10-Q's risk factors warn that an adverse outcome could bring generic competition sooner than expected and could materially reduce VOQUEZNA's sales, pricing and market share. Phathom says it believes the FDA decided correctly.

Revenue is climbing

Third-quarter revenue was $84.7 million, up from $49.5 million a year earlier, and the net loss narrowed to $13.9 million from $30.0 million. Operating loss was $85,000, against $15.3 million. For the first nine months, revenue was $217.3 million and the net loss was $61.8 million, compared with $200.1 million.

Over 2 million VOQUEZNA prescriptions had been filled by October 16. Phathom expects topline results from a mid-stage trial in eosinophilic esophagitis in the fourth quarter of 2026.

FDA comments are due November 23, and Saba's planned motion to consolidate its case with BDR's is the next move in court.

Sources

More on Phathom Pharmaceuticals

All Phathom Pharmaceuticals (PHAT) coverage →